Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	histone H3 methyltransferase activity	SETD2 SETMAR EHMT2 SETBP1 NSD1	3.08e-07	44	65	5	GO:0140938
GeneOntologyMolecularFunction	protein-lysine N-methyltransferase activity	SETD2 SETMAR EHMT2 SETBP1 NSD1	2.78e-06	68	65	5	GO:0016279
GeneOntologyMolecularFunction	lysine N-methyltransferase activity	SETD2 SETMAR EHMT2 SETBP1 NSD1	2.99e-06	69	65	5	GO:0016278
GeneOntologyMolecularFunction	histone methyltransferase activity	SETD2 SETMAR EHMT2 SETBP1 NSD1	3.45e-06	71	65	5	GO:0042054
GeneOntologyMolecularFunction	histone H3K36 methyltransferase activity	SETD2 SETMAR NSD1	9.20e-06	13	65	3	GO:0046975
GeneOntologyMolecularFunction	protein methyltransferase activity	SETD2 SETMAR EHMT2 SETBP1 NSD1	2.14e-05	103	65	5	GO:0008276
GeneOntologyMolecularFunction	N-methyltransferase activity	SETD2 SETMAR EHMT2 SETBP1 NSD1	2.35e-05	105	65	5	GO:0008170
GeneOntologyMolecularFunction	histone H3K36 dimethyltransferase activity	SETMAR NSD1	6.23e-05	4	65	2	GO:0140954
GeneOntologyMolecularFunction	S-adenosylmethionine-dependent methyltransferase activity	SETD2 SETMAR EHMT2 SETBP1 NSD1	2.43e-04	172	65	5	GO:0008757
GeneOntologyMolecularFunction	methyltransferase activity	SETD2 SETMAR EHMT2 SETBP1 NSD1	6.47e-04	213	65	5	GO:0008168
GeneOntologyMolecularFunction	transferase activity, transferring one-carbon groups	SETD2 SETMAR EHMT2 SETBP1 NSD1	8.12e-04	224	65	5	GO:0016741
GeneOntologyMolecularFunction	histone modifying activity	SETD2 SETMAR EHMT2 SETBP1 NSD1	8.96e-04	229	65	5	GO:0140993
GeneOntologyMolecularFunction	histone H3K4 methyltransferase activity	SETMAR SETBP1	1.91e-03	20	65	2	GO:0042800
GeneOntologyBiologicalProcess	response to nitrogen compound	SETD2 EHMT2 MC4R FER SCNN1A APC RGS9 IRS2 MMP2 PLD2 MMP9 F7 AGRN SORL1	2.79e-05	1272	64	14	GO:1901698
GeneOntologyBiologicalProcess	cell surface receptor protein tyrosine kinase signaling pathway	FER APC IRS2 MMP2 MMP9 BCR F7 FAM83C AR SORL1	9.43e-05	747	64	10	GO:0007169
GeneOntologyBiologicalProcess	protein localization to postsynaptic membrane	NRXN3 MYLK CACNA2D2 GPC4	9.62e-05	77	64	4	GO:1903539
GeneOntologyBiologicalProcess	macrophage migration	MTUS1 MMP2 MMP9 BCR	1.06e-04	79	64	4	GO:1905517
GeneOntologyBiologicalProcess	protein localization to postsynapse	NRXN3 MYLK CACNA2D2 GPC4	1.12e-04	80	64	4	GO:0062237
GeneOntologyBiologicalProcess	cellular response to oxygen-containing compound	CFH EHMT2 FER SCNN1A APC RGS9 IRS2 MMP2 MMP9 CR2 BCR AGRN AR SORL1	1.16e-04	1450	64	14	GO:1901701
GeneOntologyCellularComponent	Golgi lumen	HSPG2 GPC4 MUC19 F7 AGRN	2.10e-05	109	64	5	GO:0005796
HumanPheno	Neuroepithelial neoplasm	HSPG2 SETBP1 GPC4 NSD1 APC PALB2	8.06e-06	92	28	6	HP:0030063
HumanPheno	Neuroectodermal neoplasm	HSPG2 SETBP1 GPC4 NSD1 APC PALB2	9.13e-06	94	28	6	HP:0030061
HumanPheno	Nervous tissue neoplasm	HSPG2 SETBP1 GPC4 NSD1 APC PALB2	9.13e-06	94	28	6	HP:0030060
HumanPheno	Malignant neoplasm of the central nervous system	HSPG2 SETBP1 GPC4 NSD1 APC PALB2	1.23e-05	99	28	6	HP:0100836
HumanPheno	Embryonal neoplasm	SETBP1 GPC4 NSD1 APC PALB2	7.45e-05	83	28	5	HP:0002898
HumanPheno	Narrow palate	MYLK SCARF2 SETBP1 GPC4 NSD1 APC BCR	8.09e-05	202	28	7	HP:0000189
HumanPheno	Absent toenail	GPC4 APC BCR	1.36e-04	19	28	3	HP:0001802
HumanPheno	Tall stature	HSPG2 SETD2 MYLK GPC4 MC4R NSD1 AR	1.60e-04	225	28	7	HP:0000098
HumanPheno	High, narrow palate	MYLK SCARF2 GPC4 NSD1 APC BCR	1.61e-04	156	28	6	HP:0002705
HumanPheno	Long metacarpals	SCARF2 NSD1	1.74e-04	4	28	2	HP:0010493
HumanPheno	Sparse, thin scalp hair	NSD1 SPINK5	1.74e-04	4	28	2	HP:0002233
HumanPheno	Sacrococcygeal teratoma	SETBP1 NSD1	1.74e-04	4	28	2	HP:0030736
HumanPheno	Gonadal neoplasm	SETBP1 NSD1 APC AR PALB2	2.72e-04	109	28	5	HP:0010785
HumanPheno	Hypoplastic facial bones	HSPG2 SETD2 SCARF2 SETBP1 GPC4 APC MMP2 BCR	2.87e-04	331	28	8	HP:0002692
HumanPheno	Aplasia/Hypoplasia of facial bones	HSPG2 SETD2 SCARF2 SETBP1 GPC4 APC MMP2 BCR	2.93e-04	332	28	8	HP:0034261
HumanPheno	Neuroblastoma	HSPG2 GPC4 NSD1 PALB2	3.07e-04	61	28	4	HP:0003006
HumanPheno	Neuroblastic tumor	HSPG2 GPC4 NSD1 PALB2	3.07e-04	61	28	4	HP:0004376
HumanPheno	Peripheral primitive neuroectodermal neoplasm	HSPG2 GPC4 NSD1 PALB2	3.27e-04	62	28	4	HP:0030067
HumanPheno	Neoplasm of the central nervous system	HSPG2 SETBP1 GPC4 NSD1 APC PALB2	3.32e-04	178	28	6	HP:0100006
HumanPheno	Emphysema	SCNN1A NSD1 CR2 SPINK5	3.70e-04	64	28	4	HP:0002097
Domain	Post-SET_dom	SETD2 SETMAR EHMT2 NSD1	2.21e-07	16	64	4	IPR003616
Domain	PostSET	SETD2 SETMAR EHMT2 NSD1	2.21e-07	16	64	4	SM00508
Domain	POST_SET	SETD2 SETMAR EHMT2 NSD1	2.21e-07	16	64	4	PS50868
Domain	SET	SETD2 SETMAR EHMT2 NSD1	1.15e-05	41	64	4	PF00856
Domain	SET	SETD2 SETMAR EHMT2 NSD1	1.84e-05	46	64	4	SM00317
Domain	SET_dom	SETD2 SETMAR EHMT2 NSD1	2.57e-05	50	64	4	IPR001214
Domain	SET	SETD2 SETMAR EHMT2 NSD1	2.57e-05	50	64	4	PS50280
Domain	FN3	FLNC FNDC7 IGFN1 MYLK OBSCN SORL1	4.05e-05	185	64	6	SM00060
Domain	SEA	HSPG2 ADGRF1 AGRN	5.64e-05	22	64	3	PF01390
Domain	SEA	HSPG2 ADGRF1 AGRN	6.47e-05	23	64	3	PS50024
Domain	SEA_dom	HSPG2 ADGRF1 AGRN	6.47e-05	23	64	3	IPR000082
Domain	FN3_dom	FLNC FNDC7 IGFN1 MYLK OBSCN SORL1	7.98e-05	209	64	6	IPR003961
Domain	-	KLHL5 KLHL1 KLHL17	1.06e-04	27	64	3	2.130.10.80
Domain	AWS	SETD2 NSD1	1.15e-04	5	64	2	SM00570
Domain	AWS	SETD2 NSD1	1.15e-04	5	64	2	PS51215
Domain	AWS_dom	SETD2 NSD1	1.15e-04	5	64	2	IPR006560
Domain	EGF_3	HSPG2 NRXN3 SCARF2 F7 AGRN SORL1	1.52e-04	235	64	6	PS50026
Domain	EGF	HSPG2 NRXN3 SCARF2 F7 AGRN SORL1	1.52e-04	235	64	6	SM00181
Domain	EGF-like_dom	HSPG2 NRXN3 SCARF2 F7 AGRN SORL1	2.08e-04	249	64	6	IPR000742
Domain	Gal_Oxidase_b-propeller	KLHL5 KLHL1 KLHL17	2.13e-04	34	64	3	IPR015916
Domain	Laminin_EGF	HSPG2 SCARF2 AGRN	2.32e-04	35	64	3	PF00053
Domain	EGF_Lam	HSPG2 SCARF2 AGRN	2.32e-04	35	64	3	SM00180
Domain	fn3	FNDC7 IGFN1 MYLK OBSCN SORL1	2.33e-04	162	64	5	PF00041
Domain	PreSET	SETMAR EHMT2	2.40e-04	7	64	2	SM00468
Domain	Pre-SET	SETMAR EHMT2	2.40e-04	7	64	2	PF05033
Domain	Pre-SET_dom	SETMAR EHMT2	2.40e-04	7	64	2	IPR007728
Domain	PRE_SET	SETMAR EHMT2	2.40e-04	7	64	2	PS50867
Domain	EGF-like_CS	HSPG2 NRXN3 SCARF2 F7 AGRN SORL1	2.67e-04	261	64	6	IPR013032
Domain	EGF_2	HSPG2 NRXN3 SCARF2 F7 AGRN SORL1	2.90e-04	265	64	6	PS01186
Domain	LAM_G_DOMAIN	HSPG2 NRXN3 AGRN	2.97e-04	38	64	3	PS50025
Domain	Laminin_EGF	HSPG2 SCARF2 AGRN	2.97e-04	38	64	3	IPR002049
Domain	LamG	HSPG2 NRXN3 AGRN	4.60e-04	44	64	3	SM00282
Domain	FN3	FNDC7 IGFN1 MYLK OBSCN SORL1	5.98e-04	199	64	5	PS50853
Domain	Laminin_G_1	HSPG2 AGRN	6.23e-04	11	64	2	PF00054
Domain	-	MMP2 MMP9	8.80e-04	13	64	2	2.10.10.10
Domain	EGF	HSPG2 NRXN3 F7 AGRN	9.18e-04	126	64	4	PF00008
Domain	SEA	HSPG2 AGRN	1.02e-03	14	64	2	SM00200
Domain	FN_type2_col-bd	MMP2 MMP9	1.02e-03	14	64	2	IPR000562
Domain	FN2_2	MMP2 MMP9	1.02e-03	14	64	2	PS51092
Domain	fn2	MMP2 MMP9	1.02e-03	14	64	2	PF00040
Domain	FN2_1	MMP2 MMP9	1.02e-03	14	64	2	PS00023
Domain	FN2	MMP2 MMP9	1.02e-03	14	64	2	SM00059
Domain	Laminin_G	HSPG2 NRXN3 AGRN	1.04e-03	58	64	3	IPR001791
Domain	Kelch	KLHL5 KLHL1 KLHL17	1.04e-03	58	64	3	SM00612
Domain	BTB	KLHL5 KLHL1 ABTB2 KLHL17	1.06e-03	131	64	4	PF00651
Domain	Gal_Oxase/kelch_b-propeller	KLHL5 KLHL1 KLHL17	1.09e-03	59	64	3	IPR011043
Domain	BACK	KLHL5 KLHL1 KLHL17	1.14e-03	60	64	3	SM00875
Domain	Pept_M10A_Zn_BS	MMP2 MMP9	1.18e-03	15	64	2	IPR021158
Domain	BACK	KLHL5 KLHL1 KLHL17	1.20e-03	61	64	3	PF07707
Domain	BACK	KLHL5 KLHL1 KLHL17	1.20e-03	61	64	3	IPR011705
Domain	IGc2	HSPG2 IGFN1 MYLK OBSCN IGSF1	1.26e-03	235	64	5	SM00408
Domain	Ig_sub2	HSPG2 IGFN1 MYLK OBSCN IGSF1	1.26e-03	235	64	5	IPR003598
Domain	Hemopexin_CS	MMP2 MMP9	1.52e-03	17	64	2	IPR018486
Domain	Kelch_1	KLHL5 KLHL1 KLHL17	1.78e-03	70	64	3	PF01344
Domain	Kelch_1	KLHL5 KLHL1 KLHL17	1.78e-03	70	64	3	IPR006652
Domain	EGF_1	HSPG2 NRXN3 SCARF2 F7 AGRN	1.80e-03	255	64	5	PS00022
Domain	-	HSPG2 FLNC FNDC7 IGFN1 MYLK OBSCN IGSF1 SORL1	1.85e-03	663	64	8	2.60.40.10
Domain	PG_binding_1	MMP2 MMP9	2.11e-03	20	64	2	PF01471
Domain	Peptidoglycan-bd-like	MMP2 MMP9	2.11e-03	20	64	2	IPR002477
Domain	BTB	KLHL5 KLHL1 ABTB2 KLHL17	2.21e-03	160	64	4	PS50097
Domain	Kazal_1	AGRN SPINK5	2.55e-03	22	64	2	PF00050
Domain	PH	PLCL2 OBSCN IRS2 PLD2 BCR	2.63e-03	278	64	5	SM00233
Domain	PH_DOMAIN	PLCL2 OBSCN IRS2 PLD2 BCR	2.67e-03	279	64	5	PS50003
Domain	PH_domain	PLCL2 OBSCN IRS2 PLD2 BCR	2.71e-03	280	64	5	IPR001849
Domain	Ig-like_fold	HSPG2 FLNC FNDC7 IGFN1 MYLK OBSCN IGSF1 SORL1	2.74e-03	706	64	8	IPR013783
Domain	Hemopexin-like_dom	MMP2 MMP9	2.79e-03	23	64	2	IPR000585
Domain	Hemopexin-like_repeat	MMP2 MMP9	2.79e-03	23	64	2	IPR018487
Domain	M10A_MMP	MMP2 MMP9	2.79e-03	23	64	2	IPR033739
Domain	Hemopexin	MMP2 MMP9	2.79e-03	23	64	2	PF00045
Domain	HEMOPEXIN	MMP2 MMP9	2.79e-03	23	64	2	PS00024
Domain	-	MMP2 MMP9	2.79e-03	23	64	2	2.110.10.10
Domain	HEMOPEXIN_2	MMP2 MMP9	2.79e-03	23	64	2	PS51642
Domain	HX	MMP2 MMP9	2.79e-03	23	64	2	SM00120
Domain	Pept_M10A	MMP2 MMP9	2.79e-03	23	64	2	IPR021190
Domain	Peptidase_M10	MMP2 MMP9	3.04e-03	24	64	2	PF00413
Domain	BTB	KLHL5 KLHL1 ABTB2 KLHL17	3.38e-03	180	64	4	SM00225
Pathway	WP_HISTONE_MODIFICATIONS	SETD2 SETMAR EHMT2 SETBP1 NSD1	1.89e-06	65	45	5	M39374
Pathway	REACTOME_DEFECTIVE_EXT2_CAUSES_EXOSTOSES_2	HSPG2 GPC4 AGRN	1.08e-05	14	45	3	M27263
Pathway	KEGG_LYSINE_DEGRADATION	SETD2 SETMAR EHMT2 NSD1	1.12e-05	44	45	4	M13720
Pathway	REACTOME_ATTACHMENT_AND_ENTRY	HSPG2 GPC4 AGRN	2.84e-05	19	45	3	M41729
Pathway	REACTOME_DEFECTIVE_B4GALT7_CAUSES_EDS_PROGEROID_TYPE	HSPG2 GPC4 AGRN	3.34e-05	20	45	3	M27258
Pathway	REACTOME_RESPIRATORY_SYNCYTIAL_VIRUS_RSV_ATTACHMENT_AND_ENTRY	HSPG2 GPC4 AGRN	5.15e-05	23	45	3	M48234
Pathway	REACTOME_HS_GAG_DEGRADATION	HSPG2 GPC4 AGRN	5.87e-05	24	45	3	M636
Pathway	REACTOME_A_TETRASACCHARIDE_LINKER_SEQUENCE_IS_REQUIRED_FOR_GAG_SYNTHESIS	HSPG2 GPC4 AGRN	7.51e-05	26	45	3	M708
Pathway	PID_BETA_CATENIN_NUC_PATHWAY	APC MMP2 MMP9 AR	1.20e-04	80	45	4	M223
Pathway	REACTOME_HS_GAG_BIOSYNTHESIS	HSPG2 GPC4 AGRN	1.28e-04	31	45	3	M685
Pathway	REACTOME_EARLY_SARS_COV_2_INFECTION_EVENTS	HSPG2 GPC4 AGRN	2.19e-04	37	45	3	M45028
Pathway	KEGG_MEDICUS_REFERENCE_ANGII_AT1R_NOX2_SIGNALING_PATHWAY	MMP2 MMP9	2.76e-04	8	45	2	M47780
Pathway	REACTOME_VISUAL_PHOTOTRANSDUCTION	HSPG2 GPC4 RGS9 AGRN	2.84e-04	100	45	4	M27158
Pathway	REACTOME_DISEASES_ASSOCIATED_WITH_GLYCOSAMINOGLYCAN_METABOLISM	HSPG2 GPC4 AGRN	2.98e-04	41	45	3	M27257
Pathway	BIOCARTA_RECK_PATHWAY	MMP2 MMP9	3.54e-04	9	45	2	MM1579
Pathway	BIOCARTA_RECK_PATHWAY	MMP2 MMP9	3.54e-04	9	45	2	M22068
Pathway	REACTOME_PKMTS_METHYLATE_HISTONE_LYSINES	SETD2 EHMT2 NSD1	4.19e-04	46	45	3	MM14933
Pathway	REACTOME_METABOLISM_OF_FAT_SOLUBLE_VITAMINS	HSPG2 GPC4 AGRN	4.76e-04	48	45	3	M27642
Pathway	REACTOME_CHONDROITIN_SULFATE_DERMATAN_SULFATE_METABOLISM	HSPG2 GPC4 AGRN	5.36e-04	50	45	3	M678
Pathway	REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM	HSPG2 GPC4 AGRN	7.88e-04	57	45	3	M692
Pathway	WP_COMPLEMENT_AND_COAGULATION_CASCADES	CFH CR2 F7	8.30e-04	58	45	3	M39649
Pathway	WP_DENGUE2_INTERACTIONS_WITH_COMPLEMENT_AND_COAGULATION_CASCADES	CFH CR2 F7	8.72e-04	59	45	3	M48343
Pathway	WP_MALE_INFERTILITY	RGS9 MMP2 MMP9 AR	1.15e-03	145	45	4	M39856
Pathway	PID_LYSOPHOSPHOLIPID_PATHWAY	MMP2 PLD2 MMP9	1.16e-03	65	45	3	M15
Pathway	KEGG_COMPLEMENT_AND_COAGULATION_CASCADES	CFH CR2 F7	1.37e-03	69	45	3	M16894
Pathway	REACTOME_PKMTS_METHYLATE_HISTONE_LYSINES	SETD2 EHMT2 NSD1	1.43e-03	70	45	3	M27231
Pubmed	Expression of metalloproteinases MMP-2 and MMP-9 is associated to the presence of androgen receptor in epithelial ovarian tumors.	MMP2 MMP9 AR	6.23e-09	3	65	3	32718331
Pubmed	Heparanase localization during palatogenesis in mice.	HSPG2 MMP2 MMP9	6.21e-08	5	65	3	23509775
Pubmed	Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.	KLHL5 KLHL1 MYLK EHMT2 NSD1 APC IRS2 MMP2 MMP9 PLK3 KLHL17	1.03e-07	730	65	11	34857952
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	HSPG2 FLNC KIAA0930 OBSCN FBRSL1 NSD1 PCNX1 IRS2 BCR AGRN PLK3 ABTB2 KLHL17	1.11e-07	1105	65	13	35748872
Pubmed	Histone H2A ubiquitination inhibits the enzymatic activity of H3 lysine 36 methyltransferases.	SETD2 EHMT2 NSD1	1.24e-07	6	65	3	24019522
Pubmed	Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways.	MC4R APC IRS2 AR	1.36e-07	25	65	4	18992263
Pubmed	Host single nucleotide polymorphisms of MMP-9 -1562/TIMP-1 372 have gender differences in the risk of gastric intestinal metaplasia after Helicobacter pylori infection.	APC MMP2 MMP9	5.19e-07	9	65	3	19889076
Pubmed	An investigation into the human serum "interactome".	CFH KIAA0232 PEG3 F7 FAM83C PALB2	6.13e-07	162	65	6	15174051
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	CASP8AP2 RBM15 SETD2 FN3KRP FBRSL1 APC ZDBF2 BCR SORL1	1.46e-06	588	65	9	38580884
Pubmed	Spatiotemporal Localisation of Heparan Sulphate Proteoglycans throughout Mouse Lens Morphogenesis.	HSPG2 GPC4 AGRN	2.23e-06	14	65	3	37408198
Pubmed	Cytoplasmic Metadherin (MTDH) provides survival advantage under conditions of stress by acting as RNA-binding protein.	HSPG2 FLNC OBSCN IRS2 MMP2 PLD2	3.09e-06	214	65	6	22199357
Pubmed	Curcumin induces apoptosis and suppresses invasion through MAPK and MMP signaling in human monocytic leukemia SHI-1 cells.	MMP2 MMP9	3.44e-06	2	65	2	26134921
Pubmed	Association between the polymorphisms in MMP-2 and MMP-9 with adiposity and mammographic features.	MMP2 MMP9	3.44e-06	2	65	2	32394348
Pubmed	Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord.	MMP2 MMP9	3.44e-06	2	65	2	19074020
Pubmed	Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9.	MMP2 MMP9	3.44e-06	2	65	2	20129576
Pubmed	Increased activity and expression of gelatinases in ischemic colitis.	MMP2 MMP9	3.44e-06	2	65	2	17089188
Pubmed	Genetic variation in matrix metalloproteinase MMP2 and MMP9 as a risk factor for idiopathic recurrent spontaneous abortions in an Indian population.	MMP2 MMP9	3.44e-06	2	65	2	28500450
Pubmed	Early Gelatinase Activity Is Not a Determinant of Long-Term Recovery after Traumatic Brain Injury in the Immature Mouse.	MMP2 MMP9	3.44e-06	2	65	2	26588471
Pubmed	Expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in recurrent chronic rhinosinusitis with nasal polyposis.	MMP2 MMP9	3.44e-06	2	65	2	23257253
Pubmed	MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke.	MMP2 MMP9	3.44e-06	2	65	2	21707819
Pubmed	Matrix metalloproteinase (MMP)-9: A realiable marker for inflammation in early human trichinellosis.	MMP2 MMP9	3.44e-06	2	65	2	27117947
Pubmed	In vivo biodistribution of radiolabeled MMP-2/9 activatable cell-penetrating peptide probes in tumor-bearing mice.	MMP2 MMP9	3.44e-06	2	65	2	24823643
Pubmed	Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma.	MMP2 MMP9	3.44e-06	2	65	2	18187184
Pubmed	Interactions of central obesity with rs3918242 on risk of non-alcoholic fat liver disease: a preliminary case-control study.	MMP2 MMP9	3.44e-06	2	65	2	26097608
Pubmed	Serum MMP-2 and MMP-9 in patients with Behçet's disease: do their higher levels correlate to vasculo-Behçet's disease associated with aneurysm formation?	MMP2 MMP9	3.44e-06	2	65	2	17949555
Pubmed	Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9.	MMP2 MMP9	3.44e-06	2	65	2	19509016
Pubmed	NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas.	SETD2 NSD1	3.44e-06	2	65	2	28754676
Pubmed	Agrin and perlecan mediate tumorigenic processes in oral squamous cell carcinoma.	HSPG2 AGRN	3.44e-06	2	65	2	25506919
Pubmed	Emodin, aloe-emodin and rhein inhibit migration and invasion in human tongue cancer SCC-4 cells through the inhibition of gene expression of matrix metalloproteinase-9.	MMP2 MMP9	3.44e-06	2	65	2	20372784
Pubmed	Implication of matrix metalloproteinases 2 and 9 in ceramide 1-phosphate-stimulated macrophage migration.	MMP2 MMP9	3.44e-06	2	65	2	27164414
Pubmed	Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype.	MMP2 MMP9	3.44e-06	2	65	2	15609121
Pubmed	Role of gelatinases in disuse-induced skeletal muscle atrophy.	MMP2 MMP9	3.44e-06	2	65	2	19790245
Pubmed	Collagenase expression and activity is modulated by the interaction of collagen types, hypoxia, and nutrition in human lung cells.	MMP2 MMP9	3.44e-06	2	65	2	15672417
Pubmed	Active form of gelatinases in tear fluidin patients with corneal ulcer or ocular burn.	MMP2 MMP9	3.44e-06	2	65	2	12967855
Pubmed	Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma.	MMP2 MMP9	3.44e-06	2	65	2	10201949
Pubmed	Disruption of CADM1-dependent cell-cell adhesion in human oral squamous cell carcinoma cells results in tumor progression, possibly through an increase of MMP-2 and MMP-9 expression.	MMP2 MMP9	3.44e-06	2	65	2	38030062
Pubmed	Exercise attenuates matrix metalloproteinase activity in preexisting atherosclerotic plaque.	MMP2 MMP9	3.44e-06	2	65	2	21334624
Pubmed	The Inhibitory Effect of C-phycocyanin Containing Protein Extract (C-PC Extract) on Human Matrix Metalloproteinases (MMP-2 and MMP-9) in Hepatocellular Cancer Cell Line (HepG2).	MMP2 MMP9	3.44e-06	2	65	2	28357609
Pubmed	Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone.	MMP2 MMP9	3.44e-06	2	65	2	21611966
Pubmed	Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis.	SETD2 APC	3.44e-06	2	65	2	28825595
Pubmed	Matrix metalloproteinase variants associated with risk and clinical outcome of esophageal cancer.	MMP2 MMP9	3.44e-06	2	65	2	25966235
Pubmed	Growth factor-enhanced expression and activity of matrix metalloproteases in human non-small cell lung cancer cell lines.	MMP2 MMP9	3.44e-06	2	65	2	14981939
Pubmed	Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions.	SETD2 NSD1	3.44e-06	2	65	2	31060750
Pubmed	The influence of opioids on matrix metalloproteinase-2 and -9 secretion and mRNA levels in MCF-7 breast cancer cell line.	MMP2 MMP9	3.44e-06	2	65	2	20563853
Pubmed	Modulation of MMP-2 and -9 secretion by cytokines, inducers and inhibitors in human melanoma A-2058 cells.	MMP2 MMP9	3.44e-06	2	65	2	28440509
Pubmed	Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population.	MMP2 MMP9	3.44e-06	2	65	2	21958210
Pubmed	Inhibitory effects of tetrandrine on epidermal growth factor-induced invasion and migration in HT29 human colorectal adenocarcinoma cells.	MMP2 MMP9	3.44e-06	2	65	2	26648313
Pubmed	Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.	MMP2 MMP9	3.44e-06	2	65	2	19574670
Pubmed	Inhibition of MMP-2 and MMP-9 attenuates surgery-induced cognitive impairment in aged mice.	MMP2 MMP9	3.44e-06	2	65	2	37939860
Pubmed	Expression of Matrix Metalloproteinases-2/-9 is Associated With Microvessel Density in Pancreatic Cancer.	MMP2 MMP9	3.44e-06	2	65	2	26866436
Pubmed	Congenital Muscular Dystrophy 1D Causes Matrix Metalloproteinase Activation And Blood-Brain Barrier Impairment.	MMP2 MMP9	3.44e-06	2	65	2	27915985
Pubmed	The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms.	MMP2 MMP9	3.44e-06	2	65	2	16961137
Pubmed	Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis.	MMP2 MMP9	3.44e-06	2	65	2	33568081
Pubmed	Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling.	MMP2 MMP9	3.44e-06	2	65	2	15998676
Pubmed	Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease.	MMP2 MMP9	3.44e-06	2	65	2	16313894
Pubmed	Novel molecular imaging ligands targeting matrix metalloproteinases 2 and 9 for imaging of unstable atherosclerotic plaques.	MMP2 MMP9	3.44e-06	2	65	2	29190653
Pubmed	[Role of matrix metalloproteinase in transformation of subdural effusion into chronic subdural hematoma].	MMP2 MMP9	3.44e-06	2	65	2	20501425
Pubmed	Matrix metalloproteinase-2 and -9 activities in human keloids, hypertrophic and atrophic scars: a pilot study.	MMP2 MMP9	3.44e-06	2	65	2	19165813
Pubmed	[Association of gene polymorphisms of matrix metalloproteinases with reproductive losses in the first trimester of pregnancy].	MMP2 MMP9	3.44e-06	2	65	2	29369548
Pubmed	Combination of ACY-241 and JQ1 Synergistically Suppresses Metastasis of HNSCC via Regulation of MMP-2 and MMP-9.	MMP2 MMP9	3.44e-06	2	65	2	32961679
Pubmed	GPCR/EGFR cross talk is conserved in gonadal and adrenal steroidogenesis but is uniquely regulated by matrix metalloproteinases 2 and 9 in the ovary.	MMP2 MMP9	3.44e-06	2	65	2	21454403
Pubmed	Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes.	MMP2 MMP9	3.44e-06	2	65	2	18081721
Pubmed	Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro.	MMP2 MMP9	3.44e-06	2	65	2	9087449
Pubmed	Impact of MMP-2 and MMP-9 enzyme activity on wound healing, tumor growth and RACPP cleavage.	MMP2 MMP9	3.44e-06	2	65	2	30248101
Pubmed	MMP-2 and MMP-9 as prognostic markers for the early detection of urinary bladder cancer.	MMP2 MMP9	3.44e-06	2	65	2	30548095
Pubmed	Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection.	MMP2 MMP9	3.44e-06	2	65	2	15707406
Pubmed	Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms.	MMP2 MMP9	3.44e-06	2	65	2	12208863
Pubmed	Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma.	MMP2 MMP9	3.44e-06	2	65	2	28633655
Pubmed	Matrix metalloproteinase expression and activity in trophoblast-decidual tissues at organogenesis in CF-1 mouse.	MMP2 MMP9	3.44e-06	2	65	2	22714107
Pubmed	Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS).	MMP2 MMP9	3.44e-06	2	65	2	19523650
Pubmed	Blockade of MMP-2 and MMP-9 inhibits corneal lymphangiogenesis.	MMP2 MMP9	3.44e-06	2	65	2	28669039
Pubmed	Selective hydrolysis of triple-helical substrates by matrix metalloproteinase-2 and -9.	MMP2 MMP9	3.44e-06	2	65	2	12642591
Pubmed	Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Variants, Their Serum Levels, and Activities with Aortic Valve Calcification (AVC) in a Population from Western Iran.	MMP2 MMP9	3.44e-06	2	65	2	38708584
Pubmed	Expression of matrix metalloproteinases 2 and 9 in human trophoblasts of normal and preeclamptic placentas: preliminary findings.	MMP2 MMP9	3.44e-06	2	65	2	19716817
Pubmed	Red Grape Skin Polyphenols Blunt Matrix Metalloproteinase-2 and -9 Activity and Expression in Cell Models of Vascular Inflammation: Protective Role in Degenerative and Inflammatory Diseases.	MMP2 MMP9	3.44e-06	2	65	2	27589705
Pubmed	Induction of secreted matrix metalloproteinase-9 activity in human melanoma cells by extracellular matrix proteins and cytokines.	MMP2 MMP9	3.44e-06	2	65	2	16718267
Pubmed	Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia.	MMP2 MMP9	3.44e-06	2	65	2	14736853
Pubmed	Expression of matrix metalloproteinases 2 and 9 in donor liver, cirrhotic liver, and acute rejection after human liver transplantation.	MMP2 MMP9	3.44e-06	2	65	2	19100442
Pubmed	[Inhibitory effect of curcumin on MMP-2 and MMP-9 expression induced by polyethylene wear particles and its mechanism].	MMP2 MMP9	3.44e-06	2	65	2	19594013
Pubmed	The Relationship Between MMP-2 -1306C>T and MMP-9 -1562C>T Polymorphisms and the Risk and Prognosis of T-Cell Acute Lymphoblastic Leukemia in a Chinese Population: A Case-Control Study.	MMP2 MMP9	3.44e-06	2	65	2	28719899
Pubmed	Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells.	MMP2 MMP9	3.44e-06	2	65	2	12569569
Pubmed	Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier.	MMP2 MMP9	3.44e-06	2	65	2	27831901
Pubmed	Expression of metalloproteinases (MMP-2 and MMP-9) in basal-cell carcinoma.	MMP2 MMP9	3.44e-06	2	65	2	27406386
Pubmed	A critical role for matrix metalloproteinases in liver regeneration.	MMP2 MMP9	3.44e-06	2	65	2	18222481
Pubmed	Serum levels of matrix metalloproteinase 2 and matrix metalloproteinase 9 elevated in polypoidal choroidal vasculopathy but not in age-related macular degeneration.	MMP2 MMP9	3.44e-06	2	65	2	23559867
Pubmed	Modulation of MMP-2 and MMP-9 by cytokines, mitogens and inhibitors in lung cancer and malignant mesothelioma cell lines.	MMP2 MMP9	3.44e-06	2	65	2	19885578
Pubmed	Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation.	MMP2 MMP9	3.44e-06	2	65	2	22402435
Pubmed	Matrix metalloproteinases 2 and 9 are elevated in human preterm laboring uterine myometrium and exacerbate uterine contractility†.	MMP2 MMP9	3.44e-06	2	65	2	30951583
Pubmed	The Role of Matrix Metalloproteinases (MMP-2 and MMP-9) in Ageing and Longevity: Focus on Sicilian Long-Living Individuals (LLIs).	MMP2 MMP9	3.44e-06	2	65	2	32454796
Pubmed	Human cytomegalovirus interleukin-10 downregulates metalloproteinase activity and impairs endothelial cell migration and placental cytotrophoblast invasiveness in vitro.	MMP2 MMP9	3.44e-06	2	65	2	14990702
Pubmed	The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer.	FER AR	3.44e-06	2	65	2	23906537
Pubmed	Matrix metalloproteinase activity correlates with blastema formation in the regenerating MRL mouse ear hole model.	MMP2 MMP9	3.44e-06	2	65	2	12557216
Pubmed	Heavy smoking before coronary surgical procedures affects the native matrix metalloproteinase-2 and matrix metalloproteinase-9 gene expression in saphenous vein conduits.	MMP2 MMP9	3.44e-06	2	65	2	23146278
Pubmed	[Type IV collagenases (MMP-2 and MMP-9) and their substrates--intracellular proteins, hormones, cytokines, chemokines and their receptors].	MMP2 MMP9	3.44e-06	2	65	2	17718386
Pubmed	Reduced retinal angiogenesis in MMP-2-deficient mice.	MMP2 MMP9	3.44e-06	2	65	2	14638740
Pubmed	Matrix metalloproteinases improves trophoblast invasion and pregnancy potential in mice.	MMP2 MMP9	3.44e-06	2	65	2	32344273
Pubmed	Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines.	MMP2 MMP9	3.44e-06	2	65	2	15059974
Pubmed	The involvement of MMP-2 and MMP-9 in heart exercise-related angiogenesis.	MMP2 MMP9	3.44e-06	2	65	2	24195673
Pubmed	Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients.	MMP2 MMP9	3.44e-06	2	65	2	20514437
Pubmed	Casticin Inhibits A375.S2 Human Melanoma Cell Migration/Invasion through Downregulating NF-κB and Matrix Metalloproteinase-2 and -1.	MMP2 MMP9	3.44e-06	2	65	2	27007357
GeneFamily	Fibronectin type III domain containing	FNDC7 IGFN1 MYLK OBSCN SORL1	7.83e-05	160	50	5	555
GeneFamily	Zinc fingers C2H2-type\|Lysine methyltransferases\|PR/SET domain family	SETD2 EHMT2 NSD1	1.12e-04	34	50	3	487
GeneFamily	Blood group antigens\|CD molecules\|Proteoglycans	HSPG2 AGRN	1.56e-04	7	50	2	570
GeneFamily	Kelch like\|BTB domain containing	KLHL5 KLHL1 KLHL17	2.12e-04	42	50	3	617
GeneFamily	Basic leucine zipper proteins\|BTB domain containing	KLHL5 KLHL1 ABTB2 KLHL17	5.10e-04	134	50	4	861
GeneFamily	Blood group antigens\|CD molecules\|I-set domain containing\|Immunoglobulin like domain containing	HSPG2 IGFN1 MYLK OBSCN	1.01e-03	161	50	4	593
GeneFamily	Endogenous ligands\|Matrix metallopeptidases	MMP2 MMP9	1.99e-03	24	50	2	891
GeneFamily	Complement system\|Sushi domain containing	CFH CR2	4.45e-03	36	50	2	492
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	CFH CR2	1.09e-02	57	50	2	1179
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	OBSCN BCR	1.44e-02	66	50	2	722
Coexpression	GSE36476_CTRL_VS_TSST_ACT_72H_MEMORY_CD4_TCELL_YOUNG_UP	CFH SETD2 PLCL2 IRS2 PLK3 SORL1	9.82e-06	198	65	6	M5293
Coexpression	NABA_MATRISOME_PRIMARY_METASTATIC_COLORECTAL_TUMOR	GPC4 MMP2 MMP9 AGRN	1.41e-05	59	65	4	M47989
Coexpression	BOQUEST_STEM_CELL_UP	CFH KIAA0930 SETBP1 GPC4 IRS2 MMP2	4.65e-05	261	65	6	M1834
Coexpression	VALK_AML_CLUSTER_6	CFH KIAA0930 GPC4	8.24e-05	34	65	3	M4965
Coexpression	GSE36476_CTRL_VS_TSST_ACT_16H_MEMORY_CD4_TCELL_OLD_UP	SETD2 PLCL2 IRS2 CR2 SORL1	1.31e-04	197	65	5	M5295
Coexpression	GSE19888_ADENOSINE_A3R_INH_VS_INH_PRETREAT_AND_ACT_WITH_TCELL_MEMBRANES_MAST_CELL_DN	FNDC7 FN3KRP SCNN1A HSD17B14 F7	1.31e-04	197	65	5	M7345
Coexpression	GSE36476_CTRL_VS_TSST_ACT_40H_MEMORY_CD4_TCELL_YOUNG_UP	CFH SETD2 PLCL2 IRS2 SORL1	1.34e-04	198	65	5	M5289
Coexpression	GSE36476_CTRL_VS_TSST_ACT_16H_MEMORY_CD4_TCELL_YOUNG_UP	CFH SETD2 PLCL2 IRS2 SORL1	1.34e-04	198	65	5	M5287
Coexpression	GSE36476_CTRL_VS_TSST_ACT_72H_MEMORY_CD4_TCELL_OLD_UP	SETD2 PLCL2 IRS2 PLK3 SORL1	1.34e-04	198	65	5	M5302
Coexpression	GSE22886_NAIVE_VS_IGG_IGA_MEMORY_BCELL_UP	OBSCN IRS2 MMP2 CR2 SORL1	1.34e-04	198	65	5	M4432
Coexpression	GSE32423_CTRL_VS_IL7_IL4_MEMORY_CD8_TCELL_UP	KIAA0930 CACNA2D2 ARRDC4 NRK SORL1	1.40e-04	200	65	5	M5087
Coexpression	GSE2585_CTEC_VS_THYMIC_DC_DN	CFH SLC25A20 ARRDC4 MMP2 SPINK5	1.40e-04	200	65	5	M6272
ToppCell	BL-critical-LOC-Epithelial-Squamous\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	RPTN SCNN1A ATP10B ADGRF1 ABTB2 SPINK5	3.63e-07	191	65	6	3f9b8c4fb72ae6f3167b187e6715c4dcb3159f98
ToppCell	10x3'2.3-week_17-19-Mesenchymal_myocytic-stroma-muscle_stem_cell\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	CFH FLNC NRK PEG3 MMP2 IGSF1	4.48e-07	198	65	6	55e583321f60c95898d93cd0d2615c6692db52ec
ToppCell	10x3'2.3-week_17-19-Mesenchymal_myocytic-stroma\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	CFH FLNC NRK PEG3 MMP2 IGSF1	4.62e-07	199	65	6	e19b296d583f8bad3b66ee998a8153634d6fe09e
ToppCell	10x3'2.3-week_17-19-Mesenchymal_myocytic\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	CFH FLNC NRK PEG3 MMP2 IGSF1	4.62e-07	199	65	6	801887db51ac5dc5b068808ff75e3a46643398e9
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Hpse_Sema3c\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	CACNA2D2 RGS9 IGSF1 MMP9 ABTB2	9.79e-07	122	65	5	eae9d94f8510ac0f434942451d55c7260977b178
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c09-GZMK-FOS_l\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	CFH HSPG2 SETMAR FNDC7 HSD17B14	1.29e-06	129	65	5	a60935ff9c5a841899ccfe90531533ba4c546df3
ToppCell	P15-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1\|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	CFH MYLK SCARF2 MMP2 IGSF1	5.59e-06	174	65	5	3c47d069bd836599a8d40eae485c23d4d3487517
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.5\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	SCNN1A ATP10B USP54 ADGRF1 SORL1	6.42e-06	179	65	5	6e965e424eebef50f0202cff75f458be395cfca1
ToppCell	droplet-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l1-41\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CFH HSPG2 FLNC NRXN3 MMP2	7.14e-06	183	65	5	07ca2786e62eca9feecf5e54a11864a960f7641a
ToppCell	LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	HSPG2 NRXN3 MTUS1 SCNN1A USP54	7.33e-06	184	65	5	42ce855b4f8475a8298192feec785bdc69bc5bb0
ToppCell	Fetal_29-31_weeks-Mesenchymal-chondrocyte\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CFH SCARF2 NRK MMP2 ABTB2	7.53e-06	185	65	5	b8052cebb73f41abe6faf0aa847be7c8ef23ae94
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Cortical_Collecting_Duct_Intercalated_Cell_Type_A\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	NRXN3 MTUS1 ARRDC4 SCNN1A ADGRF1	7.73e-06	186	65	5	a6ef5d5944af5689b5f27bef89cd05645eedbe50
ToppCell	Substantia_nigra-Neuronal-Inhibitory\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	NRXN3 KLHL1 CACNA2D2 PEG3 ZDBF2	7.73e-06	186	65	5	9d3efe2a4feea2bc205a7e45b9b9f9ed9b3609ce
ToppCell	droplet-Lung-1m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CFH HSPG2 PEG3 MMP2 AR	7.93e-06	187	65	5	ed7ab4cf4629d96dad5c74d536fc428d0a8d4eb9
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Endothelial-lymphatic_endothelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	HSPG2 FLNC MTUS1 KRT27 MMP2	8.14e-06	188	65	5	26915db8863f4115b46a81982e187322e21600fd
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	HSPG2 FLNC MTUS1 KRT27 MMP2	8.14e-06	188	65	5	3f76c0f912f8f023ea425be7f43593b3d7f967e3
ToppCell	Substantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	NRXN3 KLHL1 CACNA2D2 PEG3 ZDBF2	8.14e-06	188	65	5	b73e8a40393c3f656e2fcfe395a761b1f985c254
ToppCell	Mesenchymal-chondrocyte\|World / Lineage, Cell type, age group and donor	CFH SCARF2 NRK MMP2 ABTB2	8.14e-06	188	65	5	7b1e3f8a941eaa68e89c562129a92314642eec66
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex-lymphatic_endothelial_cell_of_renal_cortex\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	HSPG2 FLNC MTUS1 KRT27 MMP2	8.14e-06	188	65	5	61ee7b152745164293d8a44ef91ee2393efbdca5
ToppCell	droplet-Lung-immune-endo-depleted\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH HSPG2 MYLK SCARF2 MMP2	8.35e-06	189	65	5	c3fb363bb0156ffb3367c200f548faebda64ab4a
ToppCell	droplet-Lung-immune-endo-depleted-3m\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH HSPG2 MYLK SCARF2 MMP2	8.35e-06	189	65	5	2a2953f6b1b7d070d739dcaf7285fce6e097d9e4
ToppCell	RA-10._Endothelium_II\|World / Chamber and Cluster_Paper	CFH HSPG2 NRXN3 SETBP1 BCR	8.35e-06	189	65	5	75c248b9de5e2fb7a0baa8cdbab516e575cc4394
ToppCell	droplet-Lung-3m\|Lung / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CFH HSPG2 MYLK SCARF2 MMP2	8.35e-06	189	65	5	5a636e952da9b1fd26aa17f7b129054f2da322b5
ToppCell	droplet-Lung-immune-endo-depleted-3m-Mesenchymal\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CFH HSPG2 MYLK SCARF2 MMP2	8.57e-06	190	65	5	9cd147a174017ebda23cc47b6d4552d898acd092
ToppCell	COVID-19-lung-AT2\|lung / Disease (COVID-19 only), tissue and cell type	MTUS1 CACNA2D2 SCNN1A USP54 ADGRF1	8.79e-06	191	65	5	276455a64c2c3503d5048615762eb2ee37f0ac70
ToppCell	10x5'v1-week_14-16-Mesenchymal_fibro-stroma-endosteal_fibroblast\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	FLNC NRK SETBP1 MMP2 F7	8.79e-06	191	65	5	44b1f62fdee03b157fe545f2ae6ff84f8929a8ac
ToppCell	PND14-Mesenchymal-Mesenchymal_structural\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CFH MYLK SCARF2 PEG3 MMP2	9.01e-06	192	65	5	25492568f9cbe097b7bb1db50d8b817c80ea87d7
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	MTUS1 FER SCNN1A ADGRF1 ABTB2	9.01e-06	192	65	5	f7e7491426bbd6ed29a465b58bf67acb93dbb90a
ToppCell	(0)_Normal/No_Treatment-(3)_LEPR+_perivascular_cells\|(0)_Normal/No_Treatment / Stress and Cell class	CFH MYLK ARRDC4 GPC4 AR	9.01e-06	192	65	5	7a2ad0bdae647b88e799e62767605f2f3c5a426f
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_2-D122\|Adult / Lineage, Cell type, age group and donor	NRXN3 MTUS1 CACNA2D2 GPC4 SCNN1A	9.01e-06	192	65	5	06013a07e3a873b1d1c0451643c528593ac32a9c
ToppCell	PND14-Mesenchymal-Mesenchymal_structural-Fibroblastic\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CFH MYLK SCARF2 PEG3 MMP2	9.01e-06	192	65	5	de9c1536d5aee86f9c62acbc54ca8fa581c00f17
ToppCell	RV-10._Endothelium_II\|RV / Chamber and Cluster_Paper	CFH HSPG2 NRXN3 SETBP1 BCR	9.24e-06	193	65	5	01c2df9206f1527c578e808978e58196c35e72f5
ToppCell	CF-Epithelial\|CF / Disease state, Lineage and Cell class	MTUS1 SCNN1A ATP10B ADGRF1 SPINK5	9.24e-06	193	65	5	518901c2e36a79c6189cd0d9e6d36dbd4f56a79c
ToppCell	CF-Epithelial-Epithelial_cell\|CF / Disease state, Lineage and Cell class	MTUS1 SCNN1A ATP10B ADGRF1 SPINK5	9.24e-06	193	65	5	4e3dda27c71b7fdac90d081f0d8e9ca3a8ea7820
ToppCell	Neuron-Postmitotic-Inhibitory_Neuron-MGE2\|World / Primary Cells by Cluster	KLHL5 NRXN3 MTUS1 CACNA2D2 APC	9.48e-06	194	65	5	b42fd64b0fb95434a9e4e6586f31d26114a4074b
ToppCell	Neuron-Postmitotic-Inhibitory_Neuron-MGE2-10\|World / Primary Cells by Cluster	KLHL5 NRXN3 MTUS1 CACNA2D2 APC	9.48e-06	194	65	5	81e7bc6516ab8d02ccd1c76a56a3533b788c27c8
ToppCell	PND14-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CFH MYLK SCARF2 PEG3 MMP2	9.72e-06	195	65	5	3a0cad69cfc150a27a0666f612f5294c817197d7
ToppCell	PND14-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_mature\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CFH MYLK SCARF2 PEG3 MMP2	9.72e-06	195	65	5	2b8ee7990267bb52b7e6ae03f509ffebf8908122
ToppCell	NS-moderate-d_16-33-Epithelial-Secretory\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CFH SCNN1A ATP10B ADGRF1 AGRN	9.96e-06	196	65	5	70384c1da9baed843f414cfd1403ddd586a2db07
ToppCell	AT2_cells-IPF_03\|World / lung cells shred on cell class, cell subclass, sample id	MTUS1 NRK ATP10B ADGRF1 AGRN	1.02e-05	197	65	5	5e0d222872a25bb9e9069d3dffda2844bb69874a
ToppCell	NS-critical-d_07-13\|critical / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CFH MTUS1 SCNN1A ATP10B ADGRF1	1.05e-05	198	65	5	a6e11c87b31beffb6af190c64b4ef3ee1d9dab8d
ToppCell	(06)_OLFM4+\|World / shred by cell type by condition	KLHL5 NRXN3 MTUS1 SCNN1A SORL1	1.07e-05	199	65	5	c773b9180dbfec9c19d4098dd43332e6f6050372
ToppCell	facs-Trachea-nan-3m-Mesenchymal\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HSPG2 SCARF2 PEG3 GPC4 MMP2	1.07e-05	199	65	5	67f78c070c56e44fba36542041bf7fa1c291807c
ToppCell	facs-Trachea-nan-3m-Mesenchymal-nan\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HSPG2 SCARF2 PEG3 GPC4 MMP2	1.07e-05	199	65	5	1ae244b563f85c1ee8d22698f478c842a4d9c7f5
ToppCell	Bronchial-10x5prime-Stromal-Peri/Epineurial_-NAF_endoneurial\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CFH MTUS1 NRK MMP2 USP54	1.10e-05	200	65	5	29054cf55e88e1ac81a562d8dd9af9b7c749321d
ToppCell	Parenchymal-10x5prime-Stromal-Peri/Epineurial_-NAF_endoneurial\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	CFH HSPG2 MTUS1 OBSCN USP54	1.10e-05	200	65	5	8a4c210a3130f7baedf15ecbc0f4903b97da0352
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Tac2_Myh4\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	KLHL1 CACNA2D2 RGS9 MMP2	1.83e-05	107	65	4	fc07dd90f280191bd643398eac5c8273651d0925
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Hpse_Cbln4\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	CACNA2D2 RGS9 IGSF1 ABTB2	2.43e-05	115	65	4	ac73aa06e617ed791c6ae9e38189bac74188c27b
ToppCell	frontal_cortex-Neuronal-glutamatergic_neuron-L5_PT-L5_PT_ALM_Hpgd\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	KLHL1 GPC4 MC4R MMP9	3.48e-05	126	65	4	9b04ca8a46cc30119baf6ef27711a0b2a6b4a0c9
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Nts\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	KLHL1 CACNA2D2 MC4R CR2	3.59e-05	127	65	4	ace2944328529fa029ee56c7ad3b0f283511d3bb
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NRXN3 MTUS1 SCNN1A USP54	3.93e-05	130	65	4	6434d9106ccb38786dad36fab80163dfc07b6eb7
ToppCell	PBMC-Mild-cDC_4\|Mild / Compartment, Disease Groups and Clusters	SETMAR EHMT2 SCARF2 ZNF749	4.30e-05	133	65	4	e53fbd69775a4bff61de82557342f7ac80915c4d
ToppCell	PBMC-Control-Myeloid-Neutrophil-Neutrophil-Neu_1\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	FLNC PCNX1 MMP9 ADGRF1	5.54e-05	142	65	4	191a13bba143ecdfc2bfd797c3ac191481388298
ToppCell	PBMC-Control-Myeloid-Neutrophil-Neutrophil-Neu_1\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	FLNC PCNX1 MMP9 ADGRF1	5.70e-05	143	65	4	b405dba9a83a99cc7b53ce71772bc52a0bbb0d4e
ToppCell	mild_COVID-19_(asymptomatic)-NK_CD56bright\|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2)	HSPG2 SCNN1A ZNF749 ABTB2	7.04e-05	151	65	4	2470162f4b56bc505db166a6eb0fa54847759df8
ToppCell	facs-Marrow-T-cells-24m-Myeloid-granulocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MC4R MMP9 PLK3 SORL1	7.04e-05	151	65	4	ced4f7ee377a23a804ae6fde624e8b55b79f1fd8
ToppCell	facs-Marrow-T-cells-24m-Myeloid-granulocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MC4R MMP9 PLK3 SORL1	7.04e-05	151	65	4	b52bb3b88e9a6473f571053537b8beb418678539
ToppCell	LPS_only-Epithelial_alveolar-AT_1-AT2_Progenitor\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NRXN3 MTUS1 KRT27 USP54	7.41e-05	153	65	4	e7a074ea8232bacf924be78a244a8507c7e1ebc8
ToppCell	severe_COVID-19-MAIT\|World / disease group, cell group and cell class (v2)	CFH MTUS1 OBSCN F7	7.60e-05	154	65	4	65ec7f7ef05c589903c4c9fe3849478c325fdc61
ToppCell	Frontal_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_1\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	FLNC SCARF2 NRK MMP2	7.60e-05	154	65	4	65dbb60f636562eeba3dafadae9c0c7db2b27476
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Hpse_Sema3c\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	KLHL1 CACNA2D2 IGSF1 ABTB2	7.79e-05	155	65	4	5c7b68b59244525e3714806c205a57a2daebf423
ToppCell	droplet-Lung-nan-3m-Myeloid-neutrophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.19e-05	157	65	4	3cffedafff31efb5b3259194157b54a768367459
ToppCell	droplet-Lung-nan-3m-Myeloid-Neutrophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.19e-05	157	65	4	f87e867a394b0453ebd92c592e80450caf5902cb
ToppCell	droplet-Heart-HEART_(LV+RV_ONLY)-30m-Myeloid-mast_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.19e-05	157	65	4	cca7f23485b9d1a1c96134b6ca85dc7dba0c0522
ToppCell	droplet-Heart-HEART_(LV+RV_ONLY)-30m-Myeloid\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.19e-05	157	65	4	241c983fc3fc5c98113baf27e03ff0eede611bd8
ToppCell	droplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Myeloid\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.19e-05	157	65	4	320d5ac063fd90e26f537475c328b3ae73974bc1
ToppCell	facs-Trachea-18m-Hematologic-myeloid-granulocyte-granulocyte_l8\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ARRDC4 MMP9 ABTB2 SORL1	8.19e-05	157	65	4	5098675f64342c41c5ca3551b24962d10c83e64d
ToppCell	droplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Myeloid-mast_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.19e-05	157	65	4	e4b17c267b754c5af95cdf17f629354d1a8a8ad7
ToppCell	droplet-Heart-nan-18m-Myeloid\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.39e-05	158	65	4	81a5a73090804d41429d297ba2462a842f39d380
ToppCell	droplet-Heart-nan-18m-Myeloid-cardiac_mast_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.39e-05	158	65	4	9596b7b0f6f5157a43d67d2e67fb75a2624a6bb9
ToppCell	droplet-Heart-nan-18m-Myeloid-mast_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.39e-05	158	65	4	7ebc8b778c97c0faa79e2d80c98b887fa635f901
ToppCell	facs-Lung-ENDOMUCIN-18m-Myeloid-neutrophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.39e-05	158	65	4	d43b335e6aa12d84a75b988fbd6127ff1f4af25c
ToppCell	facs-Lung-ENDOMUCIN-18m-Myeloid-Neutrophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.39e-05	158	65	4	ab12b29ce51ca2fcac469cc932391217d97145f9
ToppCell	facs-Lung-EPCAM-18m-Myeloid-neutrophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.60e-05	159	65	4	baf843dc44b072504eb1d28de55b1ee67aeec32b
ToppCell	facs-Lung-EPCAM-18m-Myeloid-Neutrophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.60e-05	159	65	4	9eb78202b9a4e8217f00e64d5142ed28c00abd04
ToppCell	facs-Lung-EPCAM-3m-Myeloid-neutrophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.81e-05	160	65	4	b73f07a0088936fbc3656a05710a67f38b4ae551
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Chrna2_Glra3\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	KLHL1 CACNA2D2 PEG3 RGS9	8.81e-05	160	65	4	0bfdaf979e6f128cba2928ce16bca4d3deff8ac9
ToppCell	facs-Lung-EPCAM-3m-Myeloid-Neutrophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	8.81e-05	160	65	4	b88876a58fea2066468e74dcc439c8561130a910
ToppCell	facs-Lung-18m-Hematologic-myeloid-neutrophil\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SCNN1A MMP9 PLK3 SORL1	9.24e-05	162	65	4	ad974426039f4952c59d27167eac24dc6ce63f5e
ToppCell	facs-Lung-18m-Hematologic-myeloid-neutrophil-neutrophil\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SCNN1A MMP9 PLK3 SORL1	9.24e-05	162	65	4	4e7e565091bce227d794a36af2e5dfc4a791efad
ToppCell	droplet-Fat-Gat\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	9.69e-05	164	65	4	c7ad946829c655038b33748dddd7d68c15489034
ToppCell	droplet-Fat-Gat-18m\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	9.69e-05	164	65	4	3aae702a23fbf1d36a6f18596c23e985581de815
ToppCell	ICU-SEP-Lymphocyte-T_NK-MAIT\|ICU-SEP / Disease, Lineage and Cell Type	CFH PLCL2 HSD17B14 CR2	9.69e-05	164	65	4	db863a44fc0dad5518c47fdbf64ea21d6f36f089
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell-Connecting_Tubule_Intercalated_Cell_Type_A\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	NRXN3 SCNN1A ADGRF1 ABTB2	9.92e-05	165	65	4	9bd332e5ede759a00a47728ea5558c215efdd77a
ToppCell	droplet-Heart-4Chambers-18m-Myeloid-cardiac_mast_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	9.92e-05	165	65	4	a761e0a36d5da8fec916d684f81e60f5590fd9ee
ToppCell	droplet-Heart-4Chambers-18m-Myeloid-mast_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	9.92e-05	165	65	4	680bdd150bc0a4e50244e57b1226a9b06a6bdbc9
ToppCell	Globus_pallidus-Endothelial-ENDOTHELIAL_TIP-Dcn_1\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	FLNC SCARF2 NRK MMP2	9.92e-05	165	65	4	570483b43ccb5831feec9337b4664814431d40b1
ToppCell	Globus_pallidus-Endothelial-ENDOTHELIAL_TIP\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	FLNC SCARF2 NRK MMP2	9.92e-05	165	65	4	2026a9a07f4d314cc05c167e491312b373468e46
ToppCell	droplet-Heart-4Chambers-18m-Myeloid\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCNN1A MMP9 PLK3 SORL1	9.92e-05	165	65	4	af423307af484661284793a08091777d998e6fba
ToppCell	facs-Lung-Endomucin-3m-Myeloid-neutrophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MMP9 PLK3 ABTB2 SORL1	1.02e-04	166	65	4	5126d8f02314717eed341d867856fd4fe16c5118
ToppCell	facs-Lung-Endomucin-3m-Myeloid-Neutrophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MMP9 PLK3 ABTB2 SORL1	1.02e-04	166	65	4	3037bdca38c3a65eacfa644219cc43c54e303749
ToppCell	PND10-Epithelial-Epithelial_Airway-Neurosecretory-Secretory-Secretory_G2M\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MTUS1 SCNN1A ATP10B MMP9	1.04e-04	167	65	4	a90f905ef38437752e2b0b71bd0322a184de1861
ToppCell	droplet-Lung-3m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l49\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	CFH SCARF2 OBSCN MMP2	1.06e-04	168	65	4	d2b91f2adc95dcfa623f8d7ca2df1c6f884da988
ToppCell	Substantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Tmem132c_(SN/VTA_(SNr))--\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	HSD17B14 ADGRF1 FAM187A	1.07e-04	63	65	3	e1b68ef6123ad084ce602b09fd1ba394785797e5
ToppCell	Substantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Tmem132c_(SN/VTA_(SNr))\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	HSD17B14 ADGRF1 FAM187A	1.07e-04	63	65	3	9bfd9ba1335a155ed9e56dd41dd3621b37d4234e
ToppCell	Substantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Tmem132c_(SN/VTA_(SNr))-\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	HSD17B14 ADGRF1 FAM187A	1.07e-04	63	65	3	9a90c761898618fc7e5e2984baa1021b74d4ac39
ToppCell	facs-Marrow-Granulocytes-18m-Myeloid-granulocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MTUS1 SCNN1A MMP9 SORL1	1.09e-04	169	65	4	a5964aef04093b460bbe29d5e2e7389f8fd2d46f
ToppCell	facs-Marrow-Granulocytes-24m-Myeloid-granulocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MTUS1 MMP9 PLK3 SORL1	1.09e-04	169	65	4	f38b52972a6c492ce2fd520a26bb3fc8db23bf85
ToppCell	facs-Marrow-Granulocytes-24m-Myeloid-granulocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MTUS1 MMP9 PLK3 SORL1	1.09e-04	169	65	4	5320da1d61806b53e0bd96bbdfdb8fd69246681b
ToppCell	COVID-19_Severe-CD4+_CTL\|World / disease group, cell group and cell class	CFH FNDC7 NRXN3 RGS9	1.09e-04	169	65	4	8c8168ac93a808d7b4756e4491db2b2979df1c1f
Drug	Cefotaxime sodium salt [64485-93-4]; Up 200; 8.4uM; PC3; HT_HG-U133A	CEP68 HSPG2 SETD2 KIAA0930 NRXN3 MYLK PEG3 PCNX1	8.67e-08	196	65	8	2072_UP
Drug	Mesoridazine besylate [32672-69-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A	CEP68 KIAA0232 APC PCNX1 IRS2 IGSF1 AGRN	1.44e-06	196	65	7	2874_DN
Drug	17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A	SETD2 KIAA0930 GPC4 PCNX1 IRS2 ABTB2 SORL1	1.54e-06	198	65	7	1650_DN
Drug	D 2163	HSPG2 MMP2 MMP9	7.90e-06	14	65	3	CID000148203
Drug	ND 322	MMP2 MMP9	8.03e-06	2	65	2	ctd:C568509
Drug	AC1Q62J9	MMP2 MMP9	8.03e-06	2	65	2	CID000475273
Drug	Ro 28-2653	MMP2 MMP9	8.03e-06	2	65	2	ctd:C453902
Drug	S 3304	MMP2 MMP9	8.03e-06	2	65	2	ctd:C503948
Drug	pipoxolan	MMP2 MMP9	8.03e-06	2	65	2	ctd:C000121
Drug	matlystatin B	MMP2 MMP9	8.03e-06	2	65	2	CID000132321
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	CEP68 FLNC KIAA0930 MTUS1 IRS2 ABTB2	1.04e-05	174	65	6	2084_UP
Drug	Loxapine succinate [27833-64-3]; Up 200; 9uM; PC3; HT_HG-U133A	HSPG2 FER SCNN1A APC IGSF1 BCR	1.66e-05	189	65	6	6694_UP
Drug	PF-00875133-00 [351322-64-0]; Up 200; 10uM; MCF7; HT_HG-U133A	CACNA2D2 APC PCNX1 IRS2 HSD17B14 PLK3	1.82e-05	192	65	6	5967_UP
Drug	Cephalosporanic acid, 7-amino [957-68-6]; Down 200; 14.6uM; MCF7; HT_HG-U133A	SETD2 KIAA0930 MTUS1 CACNA2D2 PCNX1 AR	1.87e-05	193	65	6	3258_DN
Drug	Clomiphene citrate (Z,E) [50-41-9]; Down 200; 6.6uM; PC3; HT_HG-U133A	SETD2 SETMAR MTUS1 APC PCNX1 PLD2	1.98e-05	195	65	6	6648_DN
Drug	Retrorsine [480-54-6]; Up 200; 11.4uM; MCF7; HT_HG-U133A	CACNA2D2 PLCL2 GPC4 SCNN1A HSD17B14 PLK3	2.04e-05	196	65	6	2784_UP
Drug	Alcuronium chloride [15180-03-7]; Up 200; 5.4uM; MCF7; HT_HG-U133A	GPC4 FER PCNX1 ATP10B IRS2 PLK3	2.04e-05	196	65	6	7345_UP
Drug	Guanethidine sulfate [60-02-6]; Down 200; 13.4uM; MCF7; HT_HG-U133A	SETD2 GPC4 NSD1 APC PCNX1 IRS2	2.10e-05	197	65	6	3171_DN
Drug	ICI 182,780; Down 200; 0.01uM; PC3; HT_HG-U133A	CEP68 HSPG2 KIAA0930 GPC4 PLD2 MMP9	2.16e-05	198	65	6	1238_DN
Drug	Merbromin [129-16-8]; Up 200; 5uM; PC3; HT_HG-U133A	CEP68 MTUS1 APC IRS2 PLK3 SPINK5	2.16e-05	198	65	6	7398_UP
Drug	Bethanechol chloride [590-63-6]; Up 200; 20.4uM; MCF7; HT_HG-U133A	HSPG2 MYLK ATP10B ZNF749 IRS2 SPINK5	2.22e-05	199	65	6	5539_UP
Drug	SU 1498	MMP2 MMP9	2.40e-05	3	65	2	ctd:C483044
Drug	Captopril	MMP2 MMP9	2.40e-05	3	65	2	DB01197
Drug	zosterin	MMP2 MMP9	2.40e-05	3	65	2	ctd:C070927
Drug	AMD 6221	MMP2 MMP9	2.40e-05	3	65	2	ctd:C453459
Drug	SB 3CT compound	MMP2 MMP9	2.40e-05	3	65	2	ctd:C429533
Drug	delta-(3,4-dihydroxyphenyl)-gamma-valerolactone	MMP2 MMP9	2.40e-05	3	65	2	CID000152432
Drug	4-(4-(4-fluorophenoxy)benzenesulfonylamino)tetrahydropyran-4-carboxylic acid hydroxyamide	MMP2 MMP9	2.40e-05	3	65	2	ctd:C532757
Drug	alpha-benzoylamino-1,4-naphthoquinone	MMP2 MMP9	2.40e-05	3	65	2	ctd:C109682
Drug	CP-471,358	MMP2 MMP9	2.40e-05	3	65	2	ctd:C495612
Drug	E-2-(4'-methoxybenzylidene)-benzusuberone	MMP2 MMP9	4.80e-05	4	65	2	ctd:C515537
Drug	isorhamnetin 3-O-glucoside	MMP2 MMP9	4.80e-05	4	65	2	ctd:C432511
Drug	N6L peptide	MMP2 MMP9	4.80e-05	4	65	2	ctd:C580583
Drug	inostamycin	NRK MMP2 MMP9	4.88e-05	25	65	3	CID000122746
Drug	AC1L1GXT	MYLK MMP2 MMP9 F7	5.99e-05	74	65	4	CID000003890
Drug	1 PM	MMP2 MMP9 AR	6.91e-05	28	65	3	CID000004315
Drug	TPD7 compound	MMP2 MMP9	7.98e-05	5	65	2	ctd:C000604982
Drug	CAY 10580	MMP2 MMP9	7.98e-05	5	65	2	ctd:C561931
Drug	(2S,4R)-methyl-1-acetyl-4-(N-(4-bromophenyl)sulfamoyloxy)pyrrolidine-2-carboxylate	MMP2 MMP9	7.98e-05	5	65	2	ctd:C560356
Drug	tertiary-amyl methyl ether	MMP2 MMP9	7.98e-05	5	65	2	ctd:C096680
Drug	Angiotensin Receptor Antagonists	MMP2 MMP9	7.98e-05	5	65	2	ctd:D057911
Drug	20-hydroxyeicosa-5(Z),14(Z)-dienoic acid	MMP2 MMP9	7.98e-05	5	65	2	ctd:C494665
Drug	AC1L1G2K	NRK APC MMP2 MMP9	9.83e-05	84	65	4	CID000003498
Drug	Emetine	MMP2 MMP9 AR	1.04e-04	32	65	3	ctd:D004640
Drug	varespladib methyl	MMP2 MMP9	1.19e-04	6	65	2	ctd:C545088
Drug	Alpatp	MMP2 MMP9	1.19e-04	6	65	2	CID000131722
Drug	2-Amino-5-mercapto-1,3,4-thiadiazole	MMP2 MMP9	1.19e-04	6	65	2	CID002723847
Drug	Adrenergic beta-Antagonists	MMP2 MMP9	1.19e-04	6	65	2	ctd:D000319
Drug	4-aminophenylmercuriacetate	MMP2 MMP9	1.19e-04	6	65	2	ctd:C010024
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	KIAA0930 NRXN3 MTUS1 IRS2 ABTB2	1.37e-04	173	65	5	7285_UP
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	NRXN3 MTUS1 IRS2 AGRN ABTB2	1.40e-04	174	65	5	7136_UP
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	CEP68 NRXN3 MTUS1 IRS2 ABTB2	1.44e-04	175	65	5	7245_UP
Drug	Hydrogen Sulfide	MMP2 MMP9	1.67e-04	7	65	2	ctd:D006862
Drug	tomatidine	MMP2 MMP9	1.67e-04	7	65	2	ctd:C003677
Drug	3-phenylpropylsalicylate	MMP2 AR	1.67e-04	7	65	2	CID000090607
Drug	tetracycline CMT-8	MMP2 MMP9	1.67e-04	7	65	2	ctd:C117153
Drug	AC1L3V80	NRK BCR	1.67e-04	7	65	2	CID000122770
Drug	tebuconazole	MMP2 MMP9 AR	1.89e-04	39	65	3	ctd:C087114
Drug	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide	MMP2 MMP9 AR	1.89e-04	39	65	3	ctd:C078131
Drug	16-hydroxycleroda-3,13(14)-dien-15,16-olide	APC MMP2 MMP9	1.89e-04	39	65	3	ctd:C072581
Drug	Trifluoperazine dihydrochloride [440-17-5]; Up 200; 8.4uM; MCF7; HT_HG-U133A	MYLK SCNN1A ATP10B IRS2 SPINK5	2.01e-04	188	65	5	5442_UP
Drug	Cholesterol, Dietary	IRS2 MMP2 MMP9 F7	2.08e-04	102	65	4	ctd:D002791
Drug	troglitazone; Up 200; 10uM; PC3; HG-U133A	SETMAR SLC25A20 PLCL2 IRS2 AGRN	2.11e-04	190	65	5	462_UP
Drug	Muramic acid, N-acetyl [10597-89-4]; Down 200; 13.6uM; PC3; HT_HG-U133A	MYLK PEG3 APC PCNX1 PLK3	2.11e-04	190	65	5	4582_DN
Drug	Strophantine octahydrate [11018-89-6]; Down 200; 5.4uM; PC3; HT_HG-U133A	CEP68 SETMAR APC PLD2 PALB2	2.11e-04	190	65	5	6680_DN
Drug	hexanolamine PAF	MMP2 MMP9	2.22e-04	8	65	2	CID000132080
Drug	3-caffeoyl-4-dihydrocaffeoylquinic acid	MMP2 MMP9	2.22e-04	8	65	2	ctd:C544671
Drug	cholesterol alpha-oxide	MMP2 MMP9	2.22e-04	8	65	2	ctd:C002415
Drug	solasodine	MMP2 MMP9	2.22e-04	8	65	2	ctd:C012037
Drug	Phospholipase A2 Inhibitors	MMP2 MMP9	2.22e-04	8	65	2	ctd:D064801
Drug	Marimastat	MMP2 MMP9	2.22e-04	8	65	2	DB00786
Drug	2-pyridylpiperazine	MMP2 MMP9	2.22e-04	8	65	2	CID000094459
Drug	sargahydroquinoic acid	MMP2 MMP9	2.22e-04	8	65	2	ctd:C528847
Drug	Ro 32-3555	MMP2 MMP9	2.22e-04	8	65	2	CID000193987
Drug	3-hydroxylup-20(29)-ene-27,28-dioic acid dimethyl ester	MMP2 MMP9	2.22e-04	8	65	2	ctd:C554289
Drug	Mexiletine hydrochloride [5370-01-4]; Down 200; 18.6uM; MCF7; HT_HG-U133A	MYLK SETBP1 FER APC MMP2	2.27e-04	193	65	5	3973_DN
Drug	isocycloheximide	CFH SETD2 SCARF2 NRK MC4R MMP2 MMP9 BCR AR SORL1	2.31e-04	905	65	10	CID000002900
Drug	Heliotrine [303-33-3]; Down 200; 12.8uM; PC3; HT_HG-U133A	CACNA2D2 APC PCNX1 ZNF749 PLK3	2.33e-04	194	65	5	3717_DN
Drug	CP-645525-01 [287190-82-3]; Up 200; 10uM; MCF7; HT_HG-U133A	CACNA2D2 GPC4 FER APC PLD2	2.33e-04	194	65	5	7522_UP
Drug	Prilocaine hydrochloride [1786-81-8]; Down 200; 15.6uM; PC3; HT_HG-U133A	KIAA0930 SETBP1 PLD2 AGRN PALB2	2.33e-04	194	65	5	4284_DN
Drug	Iopanoic acid [96-83-3]; Up 200; 7uM; HL60; HT_HG-U133A	HSPG2 MTUS1 SETBP1 PLCL2 PCNX1	2.33e-04	194	65	5	2965_UP
Drug	Carbachol [51-83-2]; Up 200; 21.8uM; MCF7; HT_HG-U133A	FER APC IRS2 PLD2 SPINK5	2.33e-04	194	65	5	5342_UP
Drug	Cephalosporanic acid, 7-amino [957-68-6]; Down 200; 14.6uM; PC3; HT_HG-U133A	CEP68 HSPG2 PEG3 APC AGRN	2.33e-04	194	65	5	4242_DN
Drug	Betonicine [515-25-3]; Down 200; 25.2uM; PC3; HT_HG-U133A	PEG3 IRS2 HSD17B14 AGRN PLK3	2.33e-04	194	65	5	4301_DN
Drug	2-propylpentanoic acid; Up 200; 500uM; MCF7; HT_HG-U133A_EA	GPC4 PCNX1 IRS2 PLK3 SPINK5	2.33e-04	194	65	5	1020_UP
Drug	Meptazinol hydrochloride [59263-76-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A	PEG3 PLCL2 MMP9 PLK3 AR	2.38e-04	195	65	5	7326_UP
Drug	Homosalate [118-56-9]; Down 200; 15.2uM; PC3; HT_HG-U133A	KIAA0930 NRXN3 NSD1 IRS2 PLK3	2.38e-04	195	65	5	4533_DN
Drug	Lumicolchicine gamma [6901-14-0]; Down 200; 10uM; MCF7; HT_HG-U133A	HSPG2 KIAA0930 MTUS1 APC SORL1	2.38e-04	195	65	5	3254_DN
Drug	D-cycloserine [68-41-7]; Up 200; 39.2uM; MCF7; HT_HG-U133A	HSPG2 FLNC MYLK IRS2 PLK3	2.44e-04	196	65	5	6782_UP
Drug	Metyrapone [54-36-4]; Down 200; 17.6uM; MCF7; HT_HG-U133A	CEP68 SETD2 KIAA0930 APC PLD2	2.44e-04	196	65	5	6447_DN
Drug	Hydroflumethiazide [135-09-1]; Up 200; 12uM; MCF7; HT_HG-U133A	CEP68 SETBP1 MMP2 PLD2 HSD17B14	2.44e-04	196	65	5	1687_UP
Drug	Tranylcypromine hydrochloride [1986-47-6]; Up 200; 23.6uM; PC3; HT_HG-U133A	SETD2 MTUS1 APC BCR PLK3	2.44e-04	196	65	5	2101_UP
Drug	Chloropyramine hydrochloride [6170-42-9]; Down 200; 12.2uM; MCF7; HT_HG-U133A	APC PCNX1 IRS2 HSD17B14 SPINK5	2.44e-04	196	65	5	3350_DN
Drug	Moricizine hydrochloride [31883-05-3]; Up 200; 8.6uM; MCF7; HT_HG-U133A	CACNA2D2 KIAA0232 GPC4 SCNN1A APC	2.44e-04	196	65	5	6000_UP
Drug	Fipexide hydrochloride [34161-23-4]; Down 200; 9.4uM; MCF7; HT_HG-U133A	GPC4 APC PCNX1 AGRN AR	2.50e-04	197	65	5	3176_DN
Drug	Yohimbine hydrochloride [65-19-0]; Down 200; 10.2uM; PC3; HT_HG-U133A	NSD1 APC PLD2 HSD17B14 ADGRF1	2.50e-04	197	65	5	7130_DN
Drug	Isopropamide iodide [71-81-8]; Up 200; 8.4uM; HL60; HT_HG-U133A	PLCL2 PLD2 CR2 AR ABTB2	2.50e-04	197	65	5	2720_UP
Drug	Harmaline hydrochloride dihydrate [6027-98-1]; Down 200; 14uM; HL60; HT_HG-U133A	NSD1 APC ZNF749 AGRN PLK3	2.50e-04	197	65	5	2149_DN
Drug	Bupivacaine hydrochloride [18010-40-7]; Up 200; 12.4uM; MCF7; HT_HG-U133A	CEP68 KIAA0930 SCNN1A IRS2 BCR	2.50e-04	197	65	5	5537_UP
Drug	Xylazine [7361-61-7]; Down 200; 18.2uM; PC3; HT_HG-U133A	CFH KIAA0930 MTUS1 GPC4 MMP9	2.50e-04	197	65	5	4066_DN
Disease	Sotos' syndrome	SETD2 NRK NSD1	3.53e-08	4	62	3	C0175695
Disease	Leukemia, Myelocytic, Acute	SETD2 EHMT2 SETBP1 NSD1 AGRN PALB2	1.74e-06	173	62	6	C0023467
Disease	pyoderma gangrenosum (is_marker_for)	MMP2 MMP9	4.34e-06	2	62	2	DOID:8553 (is_marker_for)
Disease	Sweet syndrome (is_marker_for)	MMP2 MMP9	4.34e-06	2	62	2	DOID:0080746 (is_marker_for)
Disease	squamous cell carcinoma (is_marker_for)	CFH MMP2 MMP9	8.36e-06	19	62	3	DOID:1749 (is_marker_for)
Disease	heart valve disease (is_marker_for)	MMP2 MMP9	1.30e-05	3	62	2	DOID:4079 (is_marker_for)
Disease	pulmonary embolism (implicated_via_orthology)	MMP2 MMP9	1.30e-05	3	62	2	DOID:9477 (implicated_via_orthology)
Disease	Sturge-Weber syndrome (is_marker_for)	MMP2 MMP9	1.30e-05	3	62	2	DOID:0111563 (is_marker_for)
Disease	Malignant neoplasm of breast	SETD2 SCARF2 SETBP1 OBSCN MMP2 USP54 PLD2 MMP9 AR PALB2 SORL1	1.31e-05	1074	62	11	C0006142
Disease	scavenger receptor class F member 2 measurement	CFH SCARF2	2.60e-05	4	62	2	EFO_0020716
Disease	Lupus Nephritis	MMP2 MMP9	2.60e-05	4	62	2	C0024143
Disease	thoracic aortic aneurysm (biomarker_via_orthology)	MMP2 MMP9	2.60e-05	4	62	2	DOID:14004 (biomarker_via_orthology)
Disease	neurexin-3-beta measurement	CFH NRXN3	2.60e-05	4	62	2	EFO_0020597
Disease	stomach carcinoma (biomarker_via_orthology)	MMP2 MMP9	2.60e-05	4	62	2	DOID:5517 (biomarker_via_orthology)
Disease	Cerebral Hemorrhage	MMP2 MMP9 F7	2.79e-05	28	62	3	C2937358
Disease	renal hypertension (implicated_via_orthology)	MMP2 MMP9	4.33e-05	5	62	2	DOID:1073 (implicated_via_orthology)
Disease	17-beta-hydroxysteroid dehydrogenase 14 measurement	EHMT2 HSD17B14	4.33e-05	5	62	2	EFO_0802231
Disease	Aortic Rupture	MMP2 MMP9	4.33e-05	5	62	2	C0003496
Disease	adrenoleukodystrophy (is_marker_for)	MMP2 MMP9	4.33e-05	5	62	2	DOID:10588 (is_marker_for)
Disease	Aortic Aneurysm, Ruptured	MMP2 MMP9	4.33e-05	5	62	2	C0741160
Disease	Pancreatic Neoplasm	APC MMP2 MMP9 PALB2	5.96e-05	100	62	4	C0030297
Disease	Malignant neoplasm of pancreas	APC MMP2 MMP9 PALB2	6.44e-05	102	62	4	C0346647
Disease	pulmonary emphysema (biomarker_via_orthology)	MMP2 MMP9	6.48e-05	6	62	2	DOID:9675 (biomarker_via_orthology)
Disease	Aortic Diseases	MMP2 MMP9	6.48e-05	6	62	2	C0003493
Disease	Neointima Formation	MMP2 MMP9	6.48e-05	6	62	2	C2936381
Disease	Neointima	MMP2 MMP9	6.48e-05	6	62	2	C2936380
Disease	ductal carcinoma in situ (is_marker_for)	MMP2 MMP9 AR	7.65e-05	39	62	3	DOID:0060074 (is_marker_for)
Disease	Aortic Aneurysm, Thoracic	MMP2 MMP9	9.06e-05	7	62	2	C0162872
Disease	Aortic Aneurysm, Thoracoabdominal	MMP2 MMP9	9.06e-05	7	62	2	C0340630
Disease	cardiomyopathy (is_marker_for)	MMP2 MMP9	9.06e-05	7	62	2	DOID:0050700 (is_marker_for)
Disease	Vasogenic Brain Edema	MYLK MMP9	1.21e-04	8	62	2	C0750969
Disease	Bone neoplasms	MMP2 MMP9	1.21e-04	8	62	2	C0005967
Disease	Cytotoxic Brain Edema	MYLK MMP9	1.21e-04	8	62	2	C0750970
Disease	Malignant Bone Neoplasm	MMP2 MMP9	1.21e-04	8	62	2	C0279530
Disease	Cytotoxic Cerebral Edema	MYLK MMP9	1.21e-04	8	62	2	C0472388
Disease	Vasogenic Cerebral Edema	MYLK MMP9	1.21e-04	8	62	2	C0472387
Disease	Brain Edema	MYLK MMP9	1.21e-04	8	62	2	C1527311
Disease	Cerebral Edema	MYLK MMP9	1.21e-04	8	62	2	C0006114
Disease	Marfan Syndrome, Type I	MMP2 MMP9	1.55e-04	9	62	2	C4721845
Disease	idiopathic pulmonary fibrosis (is_implicated_in)	SETD2 EHMT2	1.55e-04	9	62	2	DOID:0050156 (is_implicated_in)
Disease	abdominal aortic aneurysm (implicated_via_orthology)	MMP2 MMP9	1.55e-04	9	62	2	DOID:7693 (implicated_via_orthology)
Disease	Medulloblastoma	APC IRS2 PALB2	1.61e-04	50	62	3	C0025149
Disease	diabetic retinopathy (is_implicated_in)	CFH MMP2 MMP9	1.61e-04	50	62	3	DOID:8947 (is_implicated_in)
Disease	abdominal aortic aneurysm (is_marker_for)	MMP2 MMP9	1.93e-04	10	62	2	DOID:7693 (is_marker_for)
Disease	cholesteatoma (is_marker_for)	MMP2 MMP9	1.93e-04	10	62	2	DOID:869 (is_marker_for)
Disease	diabetic retinopathy (is_marker_for)	MMP2 MMP9 F7	2.03e-04	54	62	3	DOID:8947 (is_marker_for)
Disease	thoracic aortic aneurysm (is_implicated_in)	MYLK MMP9	2.36e-04	11	62	2	DOID:14004 (is_implicated_in)
Disease	Marfan Syndrome	MMP2 MMP9	2.36e-04	11	62	2	C0024796
Disease	Insulin Resistance	MC4R IRS2 AR	2.78e-04	60	62	3	C0021655
Disease	Insulin Sensitivity	MC4R IRS2 AR	2.78e-04	60	62	3	C0920563
Disease	Centriacinar Emphysema	MMP2 MMP9	2.83e-04	12	62	2	C0221227
Disease	Panacinar Emphysema	MMP2 MMP9	2.83e-04	12	62	2	C0264393
Disease	Focal Emphysema	MMP2 MMP9	2.83e-04	12	62	2	C2350878
Disease	intracranial aneurysm (is_implicated_in)	MMP2 MMP9	2.83e-04	12	62	2	DOID:10941 (is_implicated_in)
Disease	focal segmental glomerulosclerosis (biomarker_via_orthology)	MMP2 MMP9	2.83e-04	12	62	2	DOID:1312 (biomarker_via_orthology)
Disease	Craniofacial Abnormalities	HSPG2 SETBP1 GPC4 MMP2	3.30e-04	156	62	4	C0376634
Disease	Paroxysmal atrial fibrillation	CEP68 HSPG2 FBRSL1 SORL1	3.30e-04	156	62	4	C0235480
Disease	familial atrial fibrillation	CEP68 HSPG2 FBRSL1 SORL1	3.30e-04	156	62	4	C3468561
Disease	Persistent atrial fibrillation	CEP68 HSPG2 FBRSL1 SORL1	3.30e-04	156	62	4	C2585653
Disease	cholangiocarcinoma (biomarker_via_orthology)	MMP2 MMP9	3.34e-04	13	62	2	DOID:4947 (biomarker_via_orthology)
Disease	hyperglycemia (is_marker_for)	HSPG2 F7	3.34e-04	13	62	2	DOID:4195 (is_marker_for)
Disease	intracranial aneurysm (biomarker_via_orthology)	MMP2 MMP9	3.34e-04	13	62	2	DOID:10941 (biomarker_via_orthology)
Disease	skin melanoma (is_marker_for)	MMP2 MMP9	3.34e-04	13	62	2	DOID:8923 (is_marker_for)
Disease	Atrial Fibrillation	CEP68 HSPG2 FBRSL1 SORL1	3.64e-04	160	62	4	C0004238
Disease	alcohol use disorder (biomarker_via_orthology)	MMP2 MMP9	3.89e-04	14	62	2	DOID:1574 (biomarker_via_orthology)
Disease	membranous glomerulonephritis (biomarker_via_orthology)	CFH MMP9	3.89e-04	14	62	2	DOID:10976 (biomarker_via_orthology)
Disease	Diabetic Neuralgia	MMP2 MMP9	3.89e-04	14	62	2	C0751074
Disease	Diabetic Neuropathies	MMP2 MMP9	3.89e-04	14	62	2	C0011882
Disease	Asymmetric Diabetic Proximal Motor Neuropathy	MMP2 MMP9	3.89e-04	14	62	2	C0271674
Disease	Symmetric Diabetic Proximal Motor Neuropathy	MMP2 MMP9	3.89e-04	14	62	2	C0271673
Disease	Diabetic Mononeuropathy	MMP2 MMP9	3.89e-04	14	62	2	C0271678
Disease	Diabetic Autonomic Neuropathy	MMP2 MMP9	3.89e-04	14	62	2	C0271686
Disease	Diabetic Amyotrophy	MMP2 MMP9	3.89e-04	14	62	2	C0271685
Disease	Diabetic Polyneuropathies	MMP2 MMP9	3.89e-04	14	62	2	C0271680
Disease	intracranial aneurysm (is_marker_for)	MMP2 MMP9	3.89e-04	14	62	2	DOID:10941 (is_marker_for)
Disease	Diabetic Asymmetric Polyneuropathy	MMP2 MMP9	3.89e-04	14	62	2	C0393835
Disease	cholesteatoma of middle ear (is_marker_for)	MMP2 MMP9	5.11e-04	16	62	2	DOID:10964 (is_marker_for)
Disease	temporal arteritis (is_implicated_in)	MMP2 MMP9	5.11e-04	16	62	2	DOID:13375 (is_implicated_in)
Disease	endometriosis (biomarker_via_orthology)	MMP2 MMP9	5.11e-04	16	62	2	DOID:289 (biomarker_via_orthology)
Disease	esophagus squamous cell carcinoma (is_marker_for)	EHMT2 MMP2 MMP9	5.15e-04	74	62	3	DOID:3748 (is_marker_for)
Disease	Pulmonary Emphysema	MMP2 MMP9	5.79e-04	17	62	2	C0034067
Disease	ocular hypertension (biomarker_via_orthology)	MMP2 MMP9	5.79e-04	17	62	2	DOID:9282 (biomarker_via_orthology)
Disease	hypertrophic cardiomyopathy (is_marker_for)	MMP2 MMP9	5.79e-04	17	62	2	DOID:11984 (is_marker_for)
Disease	Neoplasm Invasiveness	MYLK MMP2 MMP9 SORL1	6.16e-04	184	62	4	C0027626
Disease	Glioblastoma	APC MMP2 MMP9	6.23e-04	79	62	3	C0017636
Disease	sweet liking measurement	ATP10B RGS9	6.50e-04	18	62	2	EFO_0010156
Disease	Oral Submucous Fibrosis	MMP2 MMP9	6.50e-04	18	62	2	C0029172
Disease	Colorectal Carcinoma	FLNC SETBP1 PEG3 OBSCN APC MMP2 SORL1	6.62e-04	702	62	7	C0009402
Disease	Liver carcinoma	MTUS1 APC IRS2 MMP2 MMP9 AR	6.80e-04	507	62	6	C2239176
Disease	Hypertensive disease	SCNN1A MMP2 MMP9 AR	6.94e-04	190	62	4	C0020538
Disease	Giant Cell Glioblastoma	APC MMP2 MMP9	7.46e-04	84	62	3	C0334588
Disease	glaucoma (is_marker_for)	CFH MMP9	8.05e-04	20	62	2	DOID:1686 (is_marker_for)
Disease	coagulation factor measurement	CFH F7	8.05e-04	20	62	2	EFO_0004634
Disease	Adenocarcinoma of prostate	AR PALB2	8.05e-04	20	62	2	C0007112
Disease	Mammary Carcinoma, Human	SETD2 SETBP1 MMP2 MMP9 AR PALB2	8.16e-04	525	62	6	C4704874
Disease	Mammary Neoplasms, Human	SETD2 SETBP1 MMP2 MMP9 AR PALB2	8.16e-04	525	62	6	C1257931
Disease	Mammary Neoplasms	SETD2 SETBP1 MMP2 MMP9 AR PALB2	8.32e-04	527	62	6	C1458155
Disease	gastric ulcer (biomarker_via_orthology)	MMP2 MMP9	8.89e-04	21	62	2	DOID:10808 (biomarker_via_orthology)
Disease	tissue factor measurement	CFH F7	8.89e-04	21	62	2	EFO_0010623
Disease	Breast Carcinoma	SETD2 SETBP1 MMP2 MMP9 AR PALB2	9.25e-04	538	62	6	C0678222

Protein segments in the cluster

Peptide	Gene	Start	Entry
GRGYSCDSESGPDDK	FBRSL1	201	Q9HCM7
YNATEDTSDCGRGAS	CACNA2D2	1101	Q9NY47
EASEDTKAQSYGRGS	CEP68	11	Q76N32
SDNDEGSGGATKYTI	C9orf129	111	Q5T035
SSGYRGNITAKCESS	ADGRF1	276	Q5T601
YRGRSSESSCGVDGD	BCR	231	P11274
ANATKVCGSDGVTYG	AGRN	931	O00468
GGCVYSKEEDGSTCL	EHMT2	741	Q96KQ7
QCKLGYVTADGETSG	CFH	476	P08603
QSEDSGLYFCGTRKG	FAM187A	116	A6NFU0
TKRNDNSDYCGISEG	CASP8AP2	731	Q9UKL3
ASVCSGGDSTDDGGY	ATP10B	666	O94823
DERKGCYSSGETVAG	ARRDC4	26	Q8NCT1
GKEYNSCTDTGRSDG	MMP2	241	P08253
LGNKYESCTSAGRSD	MMP2	356	P08253
DKSSSRGGSREYDTG	RBM15	101	Q96T37
TESCATSYSKDFGGG	NSD1	1446	Q96L73
ADSGEYSCQVTGSSG	HSPG2	2886	P98160
ESSSGLEQKGECSGS	RGS9	531	O75916
GQSYSACTTDGRSDG	MMP9	296	P14780
KEYSTCTSEGRGDGR	MMP9	356	P14780
RGKYTCEATNGSGAR	MYLK	101	Q15746
GGGCISQGRSYDTDQ	FN3KRP	21	Q9HA64
CSSGKVTSEYTDGSQ	MTUS1	266	Q9ULD2
DESSGEGSGSGCEYQ	GPC4	491	O75487
RSNGTGSESGKDTCD	SPINK5	761	Q9NQ38
AQGEKGLYQCSSTGE	FNDC7	491	Q5VTL7
YSGSESGADGRKAAE	KIAA0930	61	Q6ICG6
LGKFSSTLYETGGCD	PCNX1	876	Q96RV3
YEARCTGERDSGAKS	KIAA0232	1341	Q92628
GGREYDEGSVTSVGC	MUC19	1241	Q7Z5P9
SGAKTDTYVTDNGDG	FLNC	1296	Q14315
TTGYGGKLCSEDVSQ	NRXN3	226	Q9Y4C0
LIDGEDGSCSKSKGY	KRT27	391	Q7Z3Y8
QASSGESKYTGTLDC	SLC25A20	141	O43772
YTKGLEGESLGCSGS	AR	316	P10275
YAVGGRDGSSCLKSV	KLHL5	611	Q96PQ7
ECSGYIERASTSTGG	PEG3	1541	Q9GZU2
DTGEYSCEAGGQRLS	OBSCN	1416	Q5VST9
GATLQDSGRYKCEAG	OBSCN	3156	Q5VST9
DSGRYKCEAGGACSS	OBSCN	3161	Q5VST9
GSYEKASTEVAGRTC	PALB2	741	Q86YC2
ALAGSGSGSCRSDDY	IRS2	661	Q9Y4H2
ISNVDGKGTGTYSCS	IGSF1	471	Q8N6C5
GGNDGTSCLNSVERY	KLHL17	536	Q6TDP4
VNSSCGEGYKLSGSV	CR2	491	P20023
SRQEDGGVYSSSGLK	FER	706	P16591
GDTYCSKAGRRFTGQ	FAM83C	236	Q9BQN1
NASESLGKGYSDGGC	MC4R	26	P32245
TGGAELGYGCKASRS	HSD17B14	246	Q9BPX1
KDCGQYSVTLRSEGG	IGFN1	616	Q86VF2
RLGGDYGDCTKNGSD	SCNN1A	386	P37088
GRDGSCKQDGYDGSR	NRK	996	Q7Z2Y5
RGYRKISGDTCSGGD	SORL1	726	Q92673
GYSDGSKDSCKGDSG	F7	391	P08709
RARYDSGGVSNGDCS	PLCL2	46	Q9UPR0
YDDNSCLRDIGSGGK	SETMAR	96	Q53H47
TLDSGYGAGDSCRSL	ABTB2	16	Q8N961
YGSREGSVSSRSGEC	APC	96	P25054
GGFARCYEATDTETG	PLK3	71	Q9H4B4
SEDESSGLVYKSGSG	UHRF1BP1L	976	A0JNW5
TGERSYECGESSKVF	ZNF749	746	O43361
GDRCETKCSNGTYGE	SCARF2	356	Q96GP6
IDSEDKSCGYNGSKG	ZDBF2	1651	Q9HCK1
DSDGVTYALKCDSSG	SETD2	1011	Q9BYW2
KRTESSGSCQGASYE	XKR5	356	Q6UX68
KSGSYCGQSERLGQE	RPTN	266	Q6XPR3
VDSCTKRYSGSGGDG	SETBP1	1256	Q9Y6X0
GTERYTSGSKVGTCT	PLD2	71	O14939
CDRGETSQGAKYTGR	USP54	1511	Q70EL1
KLYSVGGRDGSSCLS	KLHL1	601	Q9NR64